A US consumer group has accused regulators of failing to adequately oversee safety reviews of new biotech crops.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Washington-based Centre for Science in the Public Interest said that some applications submitted by biotech companies to the US Food and Drug Administration were incomplete, while some had used faulty methods to test for allergens and evaluate toxins, reported the Associated Press.
The FDA has defended its pre-market review process but a spokesman said the agency would consider the consumer group’s report.
